Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 robot-assisted minimally invasive esophagectomies from 2020-2024.

Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.

Roswell Park-led study takes a significant step toward relief without opioid.

Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.

Sessions at San Antonio Breast Cancer Symposium address exercise, cannabis, sexual health, plus insights on treatment.

Roswell Park CEO Candace S. Johnson, PhD, introduces center’s first Physician in Chief, leaders in strategic areas

A treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with TNBC.

More than a dozen teams to share advances in blood cancer treatment and research innovations at the 2024 ASH Annual Meeting.

Nurse-executive and partnership manager honored for dedication to local heroes.

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers

Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial; results newly reported in The Lancet Oncology.

Black patients and older adults are least likely to undergo this treatment for blood cancers and hematologic disorders.

Third year in a row cancer center has been ranked on this listing, based on employee surveys.

A study demonstrates that adding a JAK2 inhibitor to standard immunosuppressive drugs does not improve prevention of acute graft-versus-host disease.

A study led by experts at Roswell Park Comprehensive Cancer Center suggests that e-cigarette use may help some people quit using combustible cigarettes. 

Research team shares new data on how XPO1 blockade may boost immune-based treatments.

Using multiomics, the team identifies novel therapeutic targets in castration-resistant prostate cancer.

Roswell Park Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.

Roswell Park researchers and partners shed light on how body composition at the time of diagnosis relates to mortality in epithelial ovarian cancer.

To improve access to lung cancer screening, Roswell Park Comprehensive Cancer Center experts have launched an online provider registry.

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer. 

Sai Yendamuri, MD, MBA, FACS, has been appointed as Chief Strategy Officer and Senior Vice President of Business Development and Outreach.

Roswell Park Comprehensive Cancer Center earned top score of 100 on Human Rights Campaign Foundation survey.